news
UK’s SARS-CoV-2 vaccine candidate is safe and induces antibody and T cell response
Data released from the Phase I/II trial of the ChAdOx1 COVID-19 vaccine candidate suggests it elicits an immune response with no adverse effects.
List view / Grid view
Coronavirus
news
COVID-19 vaccine safely induces immune response in Chinese trial
Investigators report CanSino Biologics’ Ad5-nCoV vaccine induced antibody production with mild to moderate side effects in patients.
news
UK government secures early access to 90 million doses of COVID-19 vaccines
The government has entered partnerships with Pfizer and Valneva to secure doses of several promising COVID-19 vaccines and secured COVID-19 neutralising antibody treatments from AstraZeneca.
news
Inhaled interferon beta therapy shows promise in COVID-19 trial
SNG001 diminished the risk of COVID-19 patients developing severe symptoms, reduced breathlessness and improved recovery rates.
article
Effect of COVID-19 on treatment of non-communicable diseases
Coronavirus or COVID-19 is currently the leading cause of mortality worldwide. With a patient database of 4,150,343 active cases (as of 28 June 2020), it is the most hit word on the internet today. Besides this catastrophe, the world has been facing a severe shortage of healthcare facilities, which has…
news
Johnson & Johnson to start COVID-19 vaccine trials next week
The company will start enrolment to the Ad26.COV2-S vaccine trial next week, it anticipates initial results in September.
![Novartis logo Novartis building in Stein, Switzerland [Credit: Taljat David shutterstock.com]](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/novartis-image-300x278.jpg)
![Novartis logo Novartis building in Stein, Switzerland [Credit: Taljat David shutterstock.com]](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/novartis-image-scaled-e1594985022657.jpg)
news
Novartis launches not-for-profit COVID-19 medications portfolio
The portfolio will be offered to low- and lower-middle-income countries to help financially strained healthcare systems care for COVID-19 patients.
article
Outsourcing update: the latest developments in pharma
European Pharmaceutical Review explores some of the latest developments in outsourcing, including clinical development and production agreements; acquisitions and collaborations; and expansions.
news
COVID-19 vaccine candidate gets green light for trial in China
The COVID-19 vaccine candidate, BNT162b1, has been approved for clinical trial registration by China's National Medical Products Administration (NMPA).
news
Experimental COVID-19 vaccine mRNA-1273 is safe and elicits response
Interim analysis of the Phase I trial data from 45 patients indicates mRNA-1273 can drive the production of antibodies targeting the SARS-CoV-2 spike protein.
news
Tocilizumab lowers risk of death for critical COVID-19 patients on ventilators, finds study
Patients who received tocilizumab in the retrospective, single-centre study were 45 percent less like to die and more likely to come off ventilation within 28 days.
news
Oral bacteriotherapy improved outcomes in COVID-19 patients
Clinical trial testing a live biotherapeutic in hospitalised COVID-19 patients suggests the bacteriotherapy could be promising.
news
FDA grants Fast Track designation to two COVID-19 vaccines
Two investigational SARS-CoV-2 vaccine candidates, BNT162b1 and BNT162b2, currently in clinical trials have been granted Fast Track designation by the FDA.
news
Inhaled formulation of remdesivir enters clinical trials
Gilead reveals the novel inhaled formulation of remdesivir entered Phase I trials to establish if it could be used to treat mild to moderate COVID-19.
news
TXA127 enters multiple Phase II trials in COVID-19 patients
A pharmaceutical formulation of the human angiotensin peptide, TXA127, will enter Phase II trials in hospitalised COVID-19 patients not in intensive care.
